64.5% of patients with moderate to advanced liver scarring show improved fibrosis in Boehringer Ingelheim's Survodutide Phase II trial.
Boehringer Ingelheim's Survodutide shows a breakthrough improvement in liver fibrosis in 64.5% of patients with moderate to advanced scarring (F2 and F3 fibrosis). The drug, which targets metabolic dysfunction-associated steatohepatitis (MASH), demonstrated no worsening of fibrosis in Phase II trial results. The findings were presented at the European Association for the Study of the Liver Congress and published in The New England Journal of Medicine.
June 07, 2024
7 Articles